# William Soliman
人気のポッドキャストエピソード
更新しました:
william soliman (born 15 February 1980 in Saint Denis, France) is a French basketball player who played 13 games for the French men's national basketball team in 2008 .
William Soliman: LLY Retatrutide Raises the Bar in Weight Loss
Eli Lilly (LLY) leads in weight-loss drugs as retatrutide shows strong results. William Soliman highlights competition from Amgen (AMGN) and potential upside in Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), and Altimmune (ALT).
======== Schwab Network ========
Empowering every investo…
Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often mi…
JNJ Earnings: Pharma Strength, MedTech Trouble & a Potential Spinoff
Christine Short and William Soliman break down Johnson & Johnson’s (JNJ) earnings, with revenue and EPS beats plus raised guidance overshadowed by another MedTech miss. Pharma remains the key growth engine, led by Tremfya, though competition from AbbVie (ABBV), Eli Lilly (LLY) and others remains a …
Trust Before Technology: Leading Healthcare Innovation with Integrity | William Soliman
How do you accelerate innovation without compromising ethics?
In this episode of the Notable Men Podcast, host Laura Ezzell sits down with healthcare executive, entrepreneur, investor, and pharmaceutical industry leader William Soliman, PhD, BCMAS, to explore the future of healthcare, artificial i…
Women Already Leaned In. Is Biotech and Pharma Ready to Lean In? Dr. Joanne Kamens, CEO of Women in Bio, on Leadership, Culture, Mentorship & Why the Companies That Get It Right Thrive
“This isn’t a lean-in situation. Women are leaning in. We did that already.”
So where does biotech go from here?
In this episode of The Will Soliman Podcast, William Soliman sits down with Dr. Joanne Kamens, CEO of Women in Bio, for a candid conversation about women, leadership, workplace culture…
What the Public Gets Wrong About mRNA, Biotech and Drug Development, Hear How This Trusted Industry's Insider Gets the Story, Before it Makes the News!
When did drug developers become the bad guys?
Will Soliman sits down with Anna Rose Welch, Editor of Advancing RNA, for a candid discussion on what the public often gets wrong about biotechnology and the people developing tomorrow’s medicines.
From RNA therapeutics and mRNA to gene editing, AI, pr…
AI Won’t Fix Lazy Thinking: Pharma Still Needs Brains in the Loop, Hear How One Pharma Company Does It.
The FDA is gathering industry input on the future of AI in clinical trials. In this episode, Genentech's Nikheel Kolatkar, VP, Therapeutic Area Head, Medical Operations, US Medical, and William Soliman explored not only where AI is headed but also how organizations can implement it responsibly.
Th…
From Bedside to Biogen 2.0: Daniel Quirk, Chief Medical Officer take on AI in Drug Development, Medical Affairs Standards, and Building Patient Trust in Pharma
Biogen’s Chief Medical Officer and Head of Medical Affairs, Dr. Daniel Quirk, joins William Soliman to unpack how a leading biotech is reshaping neuroscience, rare disease, and immunology in the era of AI. Listen to the end, as Daniel shares some career advice for medical students and aspiring medi…
AI, Neuroscience, and Pharma's $500 Billion Problem: A Candid Talk with BMS’s Chief Medical Officer on the Future of Drug Development to Agentic Medical Science Liaisons
In this episode of The Will Soliman Podcast, William Soliman sits down with Dr. Cristian Massacesi, high-energy Chief Medical Officer & Head of Drug Development at Bristol Myers Squibb (BMS). They explore how AI is reshaping drug discovery and clinical development, from target validation to trial e…
Drug Prices, Is Everything You’ve Been Told Wrong? What if the real reason medicines cost so much isn’t what you’ve been told?
In this episode, Dr. William Soliman sits down with Dr. Michael Ybarra, Chief Medical Officer of PhRMA, the pharmaceutical industry's largest trade organization, for a candid conversation on drug pricing, healthcare policy, pharmaceutical innovation, patient access, and the future of medicine.
Dr. …
ポッドキャスト検索エンジン
当社の Web サイトを使用して、人、場所、トピックごとに 3,828,250 ポッドキャストや 196,410,126 エピソードを検索できます。
知識への投資は最も大きな利益をもたらす。だから私はポッドキャストを聴く。
‐ Benjamin "Llamacorn" Franklin
